助手标题
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
共[193]条 当前为第1条到20条[由于搜索限制,当前仅支持显示前5页数据]
 

相关语句
superficial bladder cancer
Presently, one of the most potent immunotherapies is the application of bacillus Calmette Guerin (BCG) to prevent recurrences of the superficial bladder cancer.
      
It could as possibly prove to be an effective intravesical treatment agent for superficial bladder cancer.
      
Substantial changes have been made in the therapeutic options for the management of superficial bladder cancer in the past 5 years.
      
Treatment goals for superficial bladder cancer are complete removal of the initial tumor, prevention of disease recurrence, and inhibition of progression to invasive disease.
      
This article reviews the pros and cons of a second staging TURBT and how it may impact the management of high-grade, low-stage superficial bladder cancer.
      
Prevention of recurrent superficial bladder cancer
      
It has been proposed as an alternative to open radical cystectomy, which is the gold standard treatment of muscleinvasive or high-risk superficial bladder cancer.
      
Mycobacterium bovis BCG-based therapy is the treatment of choice for superficial bladder cancer.
      
Immunotherapy using bacille Calmette-Guérin (BCG) has gained increasing acceptance in the management of superficial bladder cancer.
      
From the presented data it is concluded that chemoimmune prophylaxis effectively prevents recurrences in superficial bladder cancer.
      
A human bladder cancer cell line was exposed to a range of concentrations of the four drugs commonly used to treat superficial bladder cancer (adriamycin, epodyl, mitomycin-c, thiotepa) for periods of 30, 60 and 120 min.
      
seemed to be a safe agent in the dog we have started to use it for prophylaxis in superficial bladder cancer in man.
      
In an effort to characterize the pathophysiological differences between the modes of action of BCG and thiotepa in the treatment of superficial bladder cancer, normal female rats received weekly intravesical instillations of both agents.
      
Tween 80 was shown to enhance significantly the cytotoxic activities of the four drugs (adriamycin, epodyl, mitomycin-c, thiotepa) most frequently administered intravesically to treat superficial bladder cancer.
      
It was demonstrated that patients with superficial bladder cancer displayed a raised spontaneous cellmediated cytotoxicity (SCMC) compared to patients with advanced bladder cancer and healthy control subjects.
      
In vitro, this was the case in patients with superficial bladder cancer as well as in patients with advanced bladder carcinoma, and in healthy control subjects.
      
The value of tumor-associated tissue inflammatory reaction in primary superficial bladder cancer
      
Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer
      
Urine specimens from 11 superficial bladder cancer patients were collected before and 5, 24, 48 and 72 h after repeated BCG instillations.
      
Intravesical administration of Bacillus Calmette-Guérin (BCG) has been shown to be effective in the treatment of patients with superficial bladder cancer.
      
 

首页上一页12345下一页尾页 

 
CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社